S. Rizvi

发表

Targeted alpha therapy of prostate cancer.

Yong Li, P. Russell, B. Allen, 2003, Methods in molecular medicine.

Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma

A. Bosserhoff, J. Kearsley, B. Allen, 2007, Cancer biology & therapy.

Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer

Yong Li, B. Allen, S. Rizvi, 2005, Clinical & Experimental Metastasis.

Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model

A. Perkins, J. Beretov, B. Allen, 2008, Cancer biology & therapy.

Mutagenesis induced by targeted alpha therapy using 213Bi-cDTPA-9.2.27 in lacZ transgenic mice

B. Allen, S. Rizvi, Harvey R. Fernandez, 2009, Cancer biology & therapy.

Targeted alpha therapy for cancer

Yong Li, J. Kearsley, B. Allen, 2004, Physics in medicine and biology.

In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A”-C595

M. Brechbiel, A. Perkins, Yong Li, 2005, Cancer biology & therapy.

Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer

B. Allen, S. Rizvi, P. Graham, 2007, Physics in medicine and biology.

In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells.

Yong Li, M. Madigan, B. Allen, 2005, Investigative ophthalmology & visual science.

In vivo studies of pharmacokinetics and efficacy of bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27

B. Allen, S. Rizvi, C. Raja, 2005, Cancer biology & therapy.

Intralesional targeted alpha therapy for metastatic melanoma

Yong Li, J. Kearsley, B. Allen, 2005, Cancer biology & therapy.

Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate.

Yong Li, J. Kearsley, B. Allen, 2005, Cancer letters.

Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma.

B. Allen, S. Rizvi, C. Apostolidis, 2011, Immunotherapy.

The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy

Yong Li, B. Allen, S. Rizvi, 2008, Physics in medicine and biology.

Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer

M. Brechbiel, B. Allen, S. Rizvi, 2007, Cancer biology & therapy.

In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer

G. Goozée, B. Allen, S. Rizvi, 2001, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206

P. Russell, J. Kearsley, J. Beretov, 2008, Cancer biology & therapy.

Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters.

A. Perkins, Yong Li, G. Robertson, 2006, Cancer letters.

Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model

Yong Li, B. Allen, S. Rizvi, 2006, Cancer biology & therapy.

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate

A. Perkins, Yong Li, J. Samra, 2004, British Journal of Cancer.

213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model

M. Ranson, S. Rizvi, Y. Li, 2002, British Journal of Cancer.

In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen

N. Bander, S. Rizvi, Y. Li, 2002, Prostate Cancer and Prostatic Diseases.

A new partial volume segmentation approach to extract bladder wall for computer-aided detection in virtual cystoscopy

Zhengrong Liang, Lihong Li, Zigang Wang, 2004, SPIE Medical Imaging.

In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes.

G. Goozée, B. Allen, S. Rizvi, 2002, Leukemia research.